[{"id":"2d466bac-cc21-4880-9a02-9ce432c80a1e","acronym":"ETCTN 10388","url":"https://clinicaltrials.gov/study/NCT04234568","created_at":"2023-12-06T21:16:22.996Z","updated_at":"2024-07-02T16:34:26.307Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors","source_id_and_acronym":"NCT04234568 - ETCTN 10388","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Triapine (3-AP)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/20/2020","start_date":" 07/20/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-13"}]